ICG writes €500m cheque for medical single-asset deal
ICG underwrote nearly half the transaction on Curium Pharma, an asset described as 'cream of the crop' by one secondaries buyer.
2 December 2020•2 mins read
SECONDARIES INVESTOR
Register to unlock this content
Daily global secondaries market news and intelligence- Curated insights to keep you ahead of GP-led and LP-led secondaries
- Faster, data-driven decision making powered by our AI interface, 'Ask PEI'
- Access to proprietary research and reports
- Selected fund performance and investor activity data
